Bioheart (USRM) Stock Price, News & Analysis

Company Overview

Bioheart, Inc. is a clinical-stage regenerative medicine company focused on the development and commercialization of autologous adult stem cell therapies for cardiovascular and soft tissue disorders. The company’s primary objective is to harness a patient’s own stem cells to promote tissue repair and restore function in individuals suffering from chronic heart failure, myocardial ischemia and other degenerative conditions.

The core of Bioheart’s technology is the Myocardia cell implantation system, a point-of-care solution that integrates proprietary cell-separation reagents with a catheter-based delivery platform. This system isolates and concentrates mononuclear cells from either bone marrow or peripheral blood and delivers them directly to the targeted tissue, with ongoing research into applications such as ischemic cardiomyopathy, non-healing diabetic ulcers and musculoskeletal repair.

Founded in 2003 and incorporated in Delaware, Bioheart is headquartered in Florida and operates primarily in the United States, with collaborations in selected international markets to advance its clinical programs. The company has successfully advanced multiple product candidates through early-stage human studies, aiming to secure regulatory approvals and strategic alliances that will support large-scale manufacturing and commercialization.

Bioheart’s management team brings together experts in cell therapy development, medical device regulation and biotechnology commercialization. Leveraging a growing intellectual property portfolio, the company continues to refine its regenerative treatment platforms and pursue partnerships designed to accelerate the adoption of its cell-based therapies in clinical practice.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0002
• Volume: 3,901 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

USRM Stock Analysis - Frequently Asked Questions

How have USRM shares performed this year?

Bioheart's stock was trading at $0.0001 at the start of the year. Since then, USRM shares have increased by 0.0% and is now trading at $0.0001.

How were Bioheart's earnings last quarter?

Bioheart Inc. (OTCMKTS:USRM) announced its earnings results on Wednesday, August, 7th. The company reported $0.00 earnings per share for the quarter. The firm had revenue of $1.30 million for the quarter.

How do I buy shares of Bioheart?

Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bioheart own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioheart investors own include Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Cannabis Wheaton Income (CBWTF), Meta Platforms (META), Nextech3D.AI (NEXCF) and Orion Energy Systems (OESX).

Company Calendar

• Last Earnings: 8/07/2019
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Business Services
• Current Symbol: OTCMKTS:USRM
• Previous Symbol: NASDAQ:BHRT
• CIK: 1388319
• Web: www.us-stemcell.com
• Phone: (954) 835-1500
• Fax: 954-845-9976
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -1.30